Comparison
CJC-1295 vs. Hexarelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Growth
CAS no.
no data
140703-51-1
Molecular weight
3647.3 g/mol
887.05 g/mol
Half-life
144 h
0.9 h
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACHis-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2Mechanism of action
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
Hexarelin
Hexarelin is a synthetic analog of the GHRP-6 family binding both the GH secretagogue receptor (GHSR-1a) and CD36. GHSR activation in the pituitary releases pulsatile growth hormone. Via CD36 in endothelium and myocardium, cardioprotective effects have been described in animal studies.
Evidence base
Highest evidence
Human trial
Human trial
Studies
3
4
of which in humans
2
3
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
3
1